cis-3-benzyl-3,7-diazabicyclo[3.3.0]octane | 172739-04-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cis-3-benzyl-3,7-diazabicyclo[3.3.0]octane
• 英文别名: (3aR,6aS)-2-benzyloctahydropyrrolo[3,4-c]pyrrole；2-benzyloctahydro-pyrrolo[3,4-c]pyrrole；2-benzyloctahydropyrrolo[3,4-c]pyrrole；cis-2-benzyloctahydropyrrolo[3,4-c]pyrrole；cis-2-Benzyl-octahydro-pyrrolo[3.4-c]pyrrole；2-benzyl-octahydro-pyrrolo[3,4-c]pyrrole；(3aR,6aS)-5-benzyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole
• CAS: 172739-04-7
• 化学式: C₁₃H₁₈N₂
• mdl: MFCD04116222
• 分子量: 202.299
• InChiKey: AOBSJQWEYXEPBK-BETUJISGSA-N

物化性质

• 沸点：
  299.6±33.0 °C(Predicted)
• 密度：
  1.074±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Cis-2-benzyloctahydropyrrolo[3,4-c]pyrrole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Cis-2-benzyloctahydropyrrolo[3,4-c]pyrrole
CAS number: 172739-04-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H18N2
Molecular weight: 202.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  cis-3-benzyl-3,7-diazabicyclo[3.3.0]octane 在 盐酸 、 potassium phosphate 、 dipotassium hydrogenphosphate 、 palladium 10% on activated carbon 、 氢气 、 三乙酰氧基硼氢化钠 作用下， 以 乙醇 、 二氯甲烷 、 methabol 、 水 、 乙酸乙酯 、 甲苯 、 乙腈 为溶剂， 60.0 ℃ 、790.82 kPa 条件下， 反应 2.0h， 生成 {5-[(S)-3-Amino-3-(3-fluorophenyl)-propyl]hexahydropyrrolo[3,4-c]pyrrol-2-yl}-(4,6-dimethylpyrimidin-5-yl)methanone tartaric acid salt
  参考文献：
  名称：

  CCR5受体拮抗剂RO5114436的实用不对称合成

  摘要：

  描述了一种实用的不对称合成3,7-二氮杂双环[3.3.0]辛烷衍生物（1）的方法，该衍生物是一类新型的强效CCR5受体拮抗剂的代表。通过使用（R）-MeOBIPHEP作为配体，通过钌催化的不对称还原胺化作用引入1的苄胺立体异构中心。通过Parikh-Doering氧化制备的醛4在还原胺化反应中无需进行后处理，不仅简化了工艺，而且克服了4的不稳定性。通过[3 + 2]环加成获得3，7-二氮杂双环[3.3.0]辛烷核心。

  DOI：

  10.1021/op100020z
• 作为产物：
  描述：

  2,5-二苄基四氢吡咯并[3,4-c]吡咯-1,3-二酮 在 1-氯乙基氯甲酸酯 、 lithium aluminium tetrahydride 作用下， 以 二氯甲烷 、 四氢呋喃 为溶剂， 生成 cis-3-benzyl-3,7-diazabicyclo[3.3.0]octane
  参考文献：
  名称：

  Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists

  摘要：

  Starting with a high-throughput screening lead, a novel series of CCR5 antagonists was developed utilizing an information-based approach. Improvement of pharmacokinetic properties for the series was pursued by SAR exploration of the lead template. The synthesis, SAR and biological profiles of the series are described. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.095

文献信息

• 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use
  申请人：ABBVIE INC.

  公开号：US20160376240A1

  公开（公告）日：2016-12-29

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  公式(I)的化合物以及药用可接受的盐、酯、酰胺或放射性标记形式，其中R1、R2、R3、R4、R5、R6和X如说明书中所定义，可用于治疗通过Tropomysin受体激酶（Trk）预防或改善的状况或疾病。公开了制备这些化合物的方法。还公开了公式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。
• [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2016191172A1

  公开（公告）日：2016-12-01

  Compounds of formula (I) that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公式(I)的化合物是成纤维细胞生长因子抑制剂（FGFR），因此可用于治疗可通过抑制FGFR治疗的疾病。还披露了包含此类化合物的药物组合物以及制备此类化合物的过程。
• Heterocylic antiviral compounds
  申请人：Lemoine Remy

  公开号：US20070191335A1

  公开（公告）日：2007-08-16

  Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R 1 -R 3 R 6c and X 1 are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV-1) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treating diseases mediated by the CCR5 receptor.

  足迹化学受体拮抗剂，特别是根据式(I)的3,7-二氮杂双环[3.3.0]辛烷化合物，其中R1-R3R6c和X1如本文所定义，是足迹化学CCR5受体的拮抗剂，可用于治疗或预防人类免疫缺陷病毒（HIV-1）感染，或治疗艾滋病或ARC。该发明还提供了用于治疗通过CCR5拮抗剂缓解的疾病的方法。该发明包括药物组合物和使用这些化合物治疗通过CCR5受体介导的疾病的方法。
• Diazabicyclic central nervous system active agents
  申请人：——

  公开号：US20020019388A1

  公开（公告）日：2002-02-14

  Compounds of formula I 1 pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

  式I1的化合物，这些化合物的药物组合物，以及利用这些组合物来控制哺乳动物的突触传递。
• [EN] SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B<br/>[FR] MODULATEURS DE NRB2, À BASE D'OCTAHYDRO-CYCLOPENTA[C] PYRROLE, À MODULATION NÉGATIVE SÉLECTIVE
  申请人：MNEMOSYNE PHARMACEUTICALS INC

  公开号：WO2015048507A1

  公开（公告）日：2015-04-02

  Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed. Such diseases include, without limitation, neurological dysfunction such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and seizure disorders; emotional disorders; depression; bipolar disorder; obsessive-compulsive disorder; and other anxiety disorders.

  揭示了选择性负性调节含有NR1/NR2B亚基的NMDA受体的化合物，包括该化合物的药物组合物，以及使用该化合物治疗疾病的方法。这些疾病包括但不限于神经功能障碍，如帕金森病、亨廷顿病、肌萎缩侧索硬化、多发性硬化和癫痫症；情绪障碍；抑郁症；躁郁症；强迫症；以及其他焦虑障碍。